Pneumonia, Bacterial

Infectious Diseases
4
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
Amikacin Inhalation SolutionPhase 3
Pfizer
PfizerNEW YORK, NY
1 program
1
ampicillin sodium/sulbactam sodiumPhase 31 trial
Active Trials
NCT01189487Completed47Est. Apr 2011
Eagle Pharmaceuticals
Eagle PharmaceuticalsNJ - Woodcliff Lake
1 program
1
CAL02Phase 21 trial
Active Trials
NCT05776004Active Not RecruitingEst. Sep 2026
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
CeftriaxonePhase 21 trial
Active Trials
NCT00111644Completed302Est. Jan 2007
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Diagnostic and Prognostic Biomarkers for Childhood Bacterial PneumoniaN/A1 trial
Pathogen and Host Directed testingN/A1 trial
Active Trials
NCT03996967CompletedEst. Apr 2021
NCT06181669Active Not RecruitingEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizerampicillin sodium/sulbactam sodium
Eagle PharmaceuticalsCAL02
RocheCeftriaxone
Allergy TherapeuticsPathogen and Host Directed testing
Allergy TherapeuticsDiagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

Clinical Trials (5)

Total enrollment: 349 patients across 5 trials

NCT01189487Pfizerampicillin sodium/sulbactam sodium

The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

Start: Oct 2010Est. completion: Apr 201147 patients
Phase 3Completed

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Start: Jul 2023Est. completion: Sep 2026
Phase 2Active Not Recruiting
NCT00111644RocheCeftriaxone

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

Start: Mar 2005Est. completion: Jan 2007302 patients
Phase 2Completed
NCT06181669Allergy TherapeuticsPathogen and Host Directed testing

Pneumonia Direct Pilot

Start: Apr 2024Est. completion: Dec 2025
N/AActive Not Recruiting
NCT03996967Allergy TherapeuticsDiagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

Start: Feb 2019Est. completion: Apr 2021
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space